Patterns in Place of Cancer Death in the State of Qatar: A Population-Based Study

Hassan Mohsen1, Pascale Haddad1, Ayman Allam2, Azza Hassan1,2,3*

1. Weill Cornell Medical College in Qatar, Doha, Qatar, 2. National Center for Cancer Care and Research, Doha, Qatar, 3. Cancer Management & Research, Medical Research Institute, Alexandria University, Egypt

*ahassan15@hmc.org.qa

Abstract

Background: International studies show that most people prefer to die at home; however, hospitals remain the most common place of death (PoD). This study aims to investigate the patterns in PoD and the associated factors, which are crucial for end-of-life cancer care enhancement.

Method: This retrospective, population-based study analyzed all registered cancer deaths in Qatar between January 1, 2006 and December 31, 2012 (n = 1,224). The main outcome measures were patient characteristics: age, gender, nationality, cancer diagnosis, year of death, and PoD. Time trends for age-standardized proportions of death in individual PoDs were evaluated using chi-square analysis. Odds ratio (OR) were determined for variables associated with the most preferred (acute palliative care unit [APCU] and hematology/oncology ward) versus least preferred (ICU and general medicine ward) PoDs in Qatar, stratified by nationality.

Results: The hematology/oncology ward was the most common PoD (32.4%; 95% CI 26.7–35.3%) followed by ICU (31.4%; 95% CI 28.7–34.3%), APCU (26.9%; 95% CI 24.3–29.6%), and general medicine ward (9.2%; 95% CI 7.6–11.1%). APCU trended upward (+0.057/year; p<0.001), while the hematology/oncology ward trended downward (−0.055/year; p<0.001). No statistically significant changes occurred in the other PoDs; home deaths remained low (0.4%; 95% CI 0.38–0.42). Qataris who died from liver cancer (OR 0.23) and aged 65 or older (OR 0.64) were less likely to die in the APCU or hematology/oncology ward (p<0.05). Non-Qataris who died from pancreatic cancer (OR 3.12) and female (OR 2.05) were more likely to die in the APCU or hematology/oncology ward (p<0.05). Both Qataris and non-Qataris who died from hematologic malignancy (OR 0.18 and 0.41, respectively) were more likely to die in the ICU or general medicine ward (p<0.05).

Conclusion: A high percentage of cancer deaths in Qatar occur in hospital. As home was the preferred PoD for most people, effective home care and hospice programs are needed to improve end-of-life cancer care.
Introduction

Cancer is a leading cause of death worldwide, and the number of deaths from cancer is expected to increase in the coming years. In 2012, nearly 8 million people died of cancer worldwide and by 2030 the World Health Organization (WHO) estimates that 21 million people will develop cancer and 13 million will die from cancer worldwide, translating to an increase of approximately 60% in cancer deaths [1]. In spite of extensive research into the management and prevention of cancer, the 5-year survival rate for all cancers is only 50–70% in developed countries [2–3]. Although improvements in early diagnosis and management have resulted in a high cure rate for some cancer types (e.g., breast, lymphoma, and prostate), there are other cancer types (e.g., pancreas, lung, liver, and esophagus) for which the survival rate remains low [2–3]. Moreover, the number of deaths from cancer is projected to increase worldwide, with the aging population and increase in chronic disease prevalence [4]. As a result, countries with aging populations are inevitably challenged with an increasing need for end-of-life care [5]. This has prompted the WHO to spearhead international recommendations on end-of-life care planning, which heavily emphasize patient preference for the place of care and death at the end of life [6–8].

Major studies on patient preferences from several countries have revealed that most people prefer to die at home with the provision of adequate care [9–11]. For most people, home represents a place of connection and comfort, a sense of normalcy and familiarity, and the opportunity to be around loved ones while enjoying a “normal” life [12–14]. As a result, several countries have made considerable efforts to enhance home care [15]. Despite these efforts, however, studies have shown that most cancer patients in Europe, North America, Taiwan, and Australia die in hospitals [16–22].

Meeting people’s preferences for end-of-life care has considerable economic implications for healthcare systems [23–24]. Approximately one-third of the annual net cancer care costs are spent during the final year of a patient’s life, with projections showing increasing annual expenditure as costs of cancer management rise and more people reach an older age [25–26]. Other research has shown that end-of-life care by hospital in-patient services is associated with costs that are three times higher than those of community palliative care services [27]. Importantly, higher spending and more aggressive treatments during the last year of life do not yield better outcomes for patients [28–32]. In fact, cancer patients who die in the hospital or ICU have a worse quality of life, and their grieving caregivers are at an increased risk of post-traumatic stress and prolonged grief disorders compared to patients who die at home with augmented hospice services [33–35]. Therefore, minimizing unnecessary hospital deaths and optimizing home and hospice utilization, in accordance with patient preferences, has become a crucial issue for healthcare policy initiatives in many countries [36–41].

Qatar is a peninsula covering an area of 11,571 km², with Saudi Arabia as its sole land border to the south and the Persian Gulf surrounding the remaining territory. Qatar has the world’s third largest natural gas reserves, which has
empowered it to become the world’s richest country per capita [42]. Healthcare is provided free of charge to its population of 2,045,239 individuals [43].

The National Center for Cancer Care and Research (NCCCR) is the only tertiary cancer care center in Qatar and was established in 2004 under the Hamad Medical Corporation (HMC), which manages a total of 8 highly specialized hospitals. The NCCCR currently comprises a 58-bed hematology/oncology ward for patients undergoing active cancer management. In July 2008, a 10-bed specialized acute palliative care unit (APCU) was established to serve as an acute unit where patients are admitted for acute symptom management. At this time, no other alternative palliative care models are offered, including home care, hospice, or subacute or chronic palliative care services. Cancer is the third leading cause of death in Qatar, accounting for almost 10% of all deaths [44].

In order to improve the quality of end-of-life cancer care and enable more people to die in their preferred place, it is crucial to analyze the changing patterns and factors associated with PoD of cancer patients. To the best of our knowledge, this is the first population-based study in the Middle East analyzing the PoD of cancer patients over a several-year period.

This study sought to investigate the changes over time in the following: (i) places of cancer death, (ii) patient profile and cancer diagnosis, and (iii) factors associated with place of cancer death and their relative importance. Then to (iv) compare our results with findings in other countries.

Methods

Data Sources
All deaths between 2006 and 2012 where cancer was the underlying cause of death were extracted from the National Registry of Deaths Database. By law in Qatar, a death must be registered, and the underlying cause of death recorded to approve burial of the deceased. The underlying cause of death is recorded in the database using the 10th edition of the International Classification of Diseases (ICD-10) codes.

Study Design and Study Population/Cohort Selection
This was a retrospective, population-based study of a decedent cohort of all patients who died as a result of any cancer type in the State of Qatar between January 1, 2006 and December 31, 2012. In the State of Qatar and other Gulf Cooperation Council (GCC) countries, the pediatric age group is defined as up to 14 years of age; therefore, we limited the analysis to individuals who died 15 years of age or older.

Variables
The place of death (PoD) was grouped into six categories: acute palliative care unit (APCU), hematology/oncology ward, general medicine (inpatient) ward,
ICU, abroad, and other (home, long-term care facility, private hospital, or ER). We grouped the other location categories together because the number of deaths occurring at those locations was very small. Explanatory variables included the following: age at death (15–24, 25–54, 55–64, 65–74, 75–84, and 85+ years), sex (male and female), cancer type (See Table 1 for ICD 10 codes), year of death, and nationality. We analyzed age as an ordered six-category variable rather than as a continuous variable to facilitate interpretation and comparison with other studies; the cut-off boundaries were chosen based on the data distribution.

**Statistical Analysis**

Descriptive statistics were calculated as percentages for total deaths, sex, nationality and cancer diagnosis by year. We then calculated the age-adjusted proportion of deaths according to the PoD. The proportions were standardized using the 2005–2010 mortality structure for Western Asia from the United Nations standard population [45] and then plotted against the year of death. We then conducted a chi-squared trend analysis to test for changes in the rate of death per PoD throughout the whole period of the study (2006-2012). The rate of change per PoD along with its standard error, 95% confidence interval and p-value were evaluated.

To investigate the different factors associated with the PoD, bivariate and multivariable logistic regression were used. The dependent variable was the PoD, which was binary with two categories: APCU and hematology/oncology ward (1) versus general medicine ward and ICU (0). Given the lack of alternative palliative care modules for providing patients with the required palliative care, families tend to believe that the hospital setting, where trained physicians can provide adequate and specialized care, is the ideal place for their relatives in the end-of-life period [53]. Therefore, APCU and hematology/oncology ward (together they makeup the NCCCR) were considered to be the most preferred PoD, whereas general medicine ward and ICU (both located at HGH, which is the main branch of Hamad Medical Corporation) to be the least preferred PoD. We assessed the association of each of the independent variables with the PoD using a bivariate analysis and report the odds ratios (OR) along with the 95%CI and p-value. The independent variables were the following: age (i.e., less than 65 years and at least 65 years), sex (i.e., male and female), nationality (i.e., Qatari and non-Qatari), cancer diagnosis (i.e., colorectal, hematological, breast, lung, liver, stomach, pancreas and other) and year of death (before 2009 and after 2009). We chose to study before and after 2009 because this year marks the point when the APCU was established. We then constructed a model including all of the independent variables in a multivariate logistic regression. Adjusted ORs along with the 95% CI and p-values were analyzed.

We then tested for interaction terms between nationality and sex in addition to nationality and age, separately. The interaction terms were found to be significant and the likelihood ratio test, comparing the original model (with no interaction terms) with the model with 2 interaction terms (nationality and sex, and
Table 1. Demographic characteristics of all deaths with cancer as the underlying cause of death in Qatar, 2006–2012 (data are shown as percentages, except for the total # of deaths/year).

| Year of Death | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | Total |
|---------------|------|------|------|------|------|------|------|-------|
| **All**       |      |      |      |      |      |      |      | 1224  |
| Total # of deaths | 129  | 125  | 164  | 195  | 197  | 189  | 225  | 1224  |
| **Sex**       |      |      |      |      |      |      |      |       |
| Male          | 58.9 | 60.0 | 53.7 | 56.9 | 50.8 | 55.0 | 53.8 | 55.1  |
| Female        | 41.1 | 40.0 | 46.3 | 43.1 | 49.2 | 45.0 | 46.2 | 44.9  |
| **Age**       |      |      |      |      |      |      |      |       |
| 15–24 years   | 2.3  | 4.8  | 2.4  | 2.6  | 2.0  | 3.2  | 1.8  | 2.6   |
| 25–34 years   | 3.9  | 3.2  | 6.1  | 6.2  | 5.6  | 5.3  | 3.1  | 4.8   |
| 35–44 years   | 10.9 | 7.2  | 7.3  | 14.9 | 11.2 | 9.0  | 8.4  | 10.0  |
| 45–54 years   | 20.9 | 21.6 | 15.2 | 20.0 | 20.3 | 19.6 | 23.1 | 20.2  |
| 55–64 years   | 20.9 | 30.4 | 31.1 | 18.5 | 28.4 | 27.0 | 26.2 | 26.0  |
| 65–74 years   | 27.1 | 16.0 | 21.3 | 24.6 | 19.3 | 19.0 | 20.9 | 21.2  |
| 75–84 years   | 10.9 | 13.6 | 14.6 | 10.8 | 12.2 | 13.8 | 13.3 | 12.7  |
| > 85 years    | 3.1  | 3.2  | 1.8  | 2.6  | 1.0  | 3.2  | 3.1  | 2.5   |
| **Nationality** |      |      |      |      |      |      |      |       |
| Qatari        | 36.4 | 55.2 | 47.6 | 40.0 | 45.7 | 45.0 | 45.3 | 44.9  |
| Non-Qatari    | 63.6 | 44.8 | 52.4 | 60.0 | 54.3 | 55.0 | 54.7 | 55.1  |
| **Cancer Diagnosis** |      |      |      |      |      |      |      |       |
| Bladder       | 1.6  | 1.6  | 3.7  | 3.0  | 1.6  | 0.9  | 2.0  |       |
| Brain         | 7.0  | 2.4  | 1.8  | 7.2  | 4.1  | 5.3  | 2.2  | 4.2   |
| Breast        | 12.4 | 11.2 | 10.4 | 14.4 | 13.7 | 13.2 | 17.3 | 13.6  |
| Ca unknown*   | 0.8  | 3.2  | 1.8  | 4.0  | 2.5  | 1.4  | 4.0  | 2.2   |
| Cervix        | 1.6  | 2.4  | 1.2  | 1.0  | 1.5  | 0.9  | 1.3  |       |
| Colorectal    | 6.2  | 8.0  | 9.8  | 10.7 | 12.7 | 8.0  | 8.5  |       |
| Esophagus     | 4.7  | 1.6  | 0.5  | 2.0  | 3.2  | 0.9  | 1.7  |       |
| Gallbladder   | 2.3  | 1.6  | 1.8  | 1.0  | 3.0  | 1.1  | 1.8  |       |
| Head & Neck   | 3.9  | 6.4  | 4.9  | 3.6  | 1.5  | 3.2  | 5.3  | 4.0   |
| Hematologic   | 16.3 | 16.0 | 14.0 | 17.4 | 14.2 | 12.2 | 11.1 | 14.2  |
| Kidney        | 4.7  | 2.4  | 1.8  | 2.6  | 1.5  | 3.2  | 0.9  | 2.3   |
| Liver         | 7.8  | 8.8  | 9.1  | 5.6  | 6.6  | 10.6 | 6.7  | 7.8   |
| Lung          | 13.2 | 12.8 | 16.5 | 13.3 | 16.8 | 10.6 | 10.2 | 13.2  |
| Melanoma      | 0.8  | 0.0  | 0.0  | 0.5  | 0.5  | 0.4  | 0.6  |       |
| Mesothelioma  | 0    | 0    | 0    | 0.5  | 0.5  | 0.4  | 0.2  |       |
| Neuroendocrine| 0.8  | 0    | 0    | 0.5  | 0    | 0.9  | 0.3  |       |
| Omentum       | 0    | 0.8  | 0    | 0    | 0.5  | 0    | 0    | 0.2   |
| Ovary         | 2.3  | 4.0  | 1.8  | 5.1  | 3    | 1.1  | 3.6  | 3.0   |
| Pancreas      | 3.1  | 4.8  | 6.1  | 6.2  | 4.1  | 5.8  | 6.7  | 5.4   |
| Prostate      | 0.8  | 1.6  | 4.9  | 4.1  | 1.5  | 2.6  | 4.0  | 2.9   |
| Sarcoma       | 1.6  | 3.2  | 2.4  | 3.1  | 1.5  | 2.1  | 1.3  | 2.1   |
| SCC Skin†     | 0    | 0    | 0    | 0    | 0.5  | 0.4  | 0.2  |       |
| Small Intestine| 0   | 0    | 1.0  | 1.0  | 0    | 0.4  | 0.4  |       |
| Stomach       | 7.0  | 4.8  | 4.3  | 4.6  | 4.6  | 4.8  | 8.0  | 5.5   |
| Testis        | 0.8  | 0    | 0    | 0    | 0.5  | 0    | 0    | 0.2   |
| Thymoma       | 0    | 0    | 0    | 0    | 0.5  | 0    | 0.1  |       |
| Thyroid       | 0    | 0.8  | 1.2  | 0    | 1.0  | 0.5  | 0.4  | 0.6   |
| Uterus        | 0.8  | 1.6  | 1.8  | 0    | 0.5  | 1.1  | 2.2  | 1.1   |
| Vagina        | 0    | 0    | 0.6  | 0.5  | 0    | 0    | 0    | 0.2   |
nationality and age), was also found to be significant. Rather than reporting the model with interaction terms, we stratified our model by nationality. We used adjusted ORs, which were stratified by nationality along with the 95% CI and p-values. p \leq 0.05 was considered significant. All analyses were conducted using Stata version 13.

**Ethics and Permission**

This study was approved by The Research Ethics Committee, HMC Medical Research Center, Qatar.

**Results**

**Descriptive Analysis**

In total, 1,224 cancer deaths occurred during the period of January 1, 2006 to December 31, 2012 (Table 1). The annual number of cancer deaths progressively increased from 129 in 2006 to 225 in 2012. The mean age was 58.60 years with an SD of 15.37. More men than women died of cancer over the entire study period, with males constituting 55.07% of deaths and females 44.93%, in addition to 44.85% being Qatari and 55.15% being non-Qatari. The five most common causes of cancer death, accounting for 49.5% of all cancer deaths, were hematologic (14.2%), breast (13.6%), lung (13.2%), colorectal (8.5%), and liver (7.8%) cancer. The most common PoD was the hematology/oncology ward with 28.7% (n=351), followed by the ICU with 27.8% (n=340), the APCU with 23.8% (n=291), and the HMC general medicine ward with 7.7% (n=94). Individuals who died at home, in the ER, or in a long-term facility constituted only 0.4% (n=5), 4.5% (n=55), and 0.7% (n=9) of the sample, respectively. Finally, those who died...
abroad and in private hospitals in Qatar accounted for 6.0% (n=73) and 0.2% (n=3) of the sample, respectively.

**Trend Analysis**

Throughout the study period, the hematology/oncology ward was the most common PoD (32.4%; 95% CI 26.7–35.3), followed by the ICU (31.4%; 95% CI 28.7–34.3), APCU (26.9%; 95% CI 24.3–29.6) and general medicine ward (9.2%; 95% CI 7.6–11.1). Before 2009, the hematology/oncology ward was the most common PoD (56.4%; 95% CI 51.2–61.5), followed by the ICU (27.9%; 95% CI 23.4–32.8), general medicine ward (12.5%; 95% CI 9.3–16.3) and APCU (3.2%; 95% CI 1.7–5.5). After 2009, the APCU was the most common PoD (39.5%; 95% CI 35.9–43.2), followed by the ICU (33.3; 95% CI 29.8–36.9), hematology/oncology ward (19.7%; 95% CI 16.8–22.8) and general medicine ward (7.5%; 95% CI 5.7–9.7) (Fig. 1). Trend analysis for the APCU showed a constant increase (annual increase rate in the PoD of 0.057 per year; 95% CI 0.031–0.083; p<0.001), whereas the hematology/oncology ward showed a constant downward trend (annual decrease rate in PoD of −0.055 per year; 95% CI: −0.079—−0.031; p<0.001) (Table 2). No statistically significant changes occurred in the other PoDs.

**Factors associated with the place where cancer patients died**

At the bivariate level, the risk of death at the APCU/hematology-oncology ward among females was 1.45 times higher than that among males (95% CI 1.13–1.85) (Table 3). Patients with hematological and liver cancer were less likely to die in the APCU/hematology-oncology ward (OR: 0.26, 95% CI 0.15–0.45 and OR: 0.48, 95% CI 0.27–0.88, respectively) than those with colorectal cancer. At the multivariate level, the same variables were significantly associated with death at the APCU/hematology-oncology ward, where females were more likely than males (OR: 1.37, 95% CI 1.03–1.82) and patients with hematological or liver cancer were less likely than those with colorectal cancer (OR: 0.28, 95% CI 0.16–0.48 and OR: 0.53, 95% CI 0.29–0.96, respectively).

Adjusted OR stratified by nationality. Qataris aged 65 years and older were less likely to die in the APCU/hematology-oncology ward (OR: 0.64, 95% CI 0.43–0.97) compared to those younger than 65 years (Table 4). Additionally, Qataris with hematologic and liver cancers were less likely to die in the APCU/hematology-oncology ward (OR: 0.18 p<0.001 and OR: 0.23, p=0.002, respectively) than Qataris with colorectal cancer.

Among non-Qataris, females were more likely to die in the APCU/hematology-oncology ward than males (OR: 2.05 95% CI 1.39-3.04). Additionally, non-Qataris with hematological cancer were less likely to die in the APCU/hematology-oncology ward than those with colorectal cancer (OR: 0.41, 95% CI 0.20-0.83). However, non-Qataris with pancreatic cancer were more likely to die
in the APCU/hematology-oncology ward than non-Qataris with colorectal cancer (OR: 3.12, 95% CI 1.17–8.31).

**Discussion**

Our population-based study found that an alarmingly high number of cancer deaths occurred in an acute care hospital setting, with only 0.4% of cancer deaths occurring at home. This is markedly different from the patterns of cancer deaths found in other developed countries (Fig. 2) [16–18, 20–22, 47–49]. Interestingly,

| Place of death                     | Rate of Change | 95% CI       | p-value   |
|-----------------------------------|----------------|--------------|-----------|
| Hematology/oncology ward          | −0.055         | −0.079–−0.031| <0.001*   |
| Acute palliative care unit        | 0.057          | 0.031–0.083  | <0.001*   |
| General medicine ward             | 0.003          | −0.021–0.022 | 0.974     |
| Intensive care unit               | 0.006          | −0.019–0.031 | 0.525     |
| Abroad                            | 0.008          | −0.008–0.024 | 0.177     |
| Other                             | −0.003         | −0.019–0.013 | 0.590     |

*p*<0.05.
this high rate of hospital deaths has been reported in one neighboring gulf country; a study in Kuwait analyzed the place of death of patients who died from cancer in 2009 and found that 98.7% of deaths occurred in hospital, whereas 1.0% occurred at home. To the best of our knowledge, this is the first population-based study in the Middle East analyzing the PoD of cancer patients over a several-year period.

After 2009, we observed a steady downward trend in deaths occurring in the hematology/oncology ward, mirrored by an upward trend in deaths occurring in the acute palliative care unit (APCU), which was confirmed by statistical modeling. This trend coincides with the launch of our APCU in July 2008, which provides terminal cancer patients with much-needed specialized palliative care toward the end of life. Before its initiation, both terminal patients and patients receiving active treatment were kept together in one ward, limiting the available resources and making healthcare delivery less than optimal. Despite this promising trend, there were no statistically significant changes in the other studied places of death, possibly because the palliative care service is still new and growing, and during the first three years, the admission criteria were constantly being modified. In that time, there was also a relative lack of awareness by

### Table 3. Unadjusted and adjusted odds ratios along with 95% CIs of variables associated with the place of death (APCU/hematology-oncology versus general medicine ward/ICU) in Qatar, 2006–2012.

|                      | Unadjusted OR | 95% CI          | p-value | Adjusted OR | 95% CI          | p-value |
|----------------------|---------------|-----------------|---------|-------------|-----------------|---------|
| **Age**              |               |                 |         |             |                 |         |
| <65 years            | 1.00          | 1.00            |         | 1.00        | 1.00            |         |
| ≥65 years            | 0.93          | 0.72–1.20       | 0.92    | 0.70–1.20   |                 |         |
| **Sex**              |               |                 |         |             |                 |         |
| Male                 | 1.00          | 1.00            |         | 1.00        | 1.00            |         |
| Female               | 1.45          | 1.13–1.85       | 1.37    | 1.03–1.82   |                 |         |
| **Nationality**      |               |                 |         |             |                 |         |
| Qatari               | 1.00          | 1.00            |         | 1.00        | 1.00            |         |
| Non-Qatari           | 0.98          | 0.77–1.26       | 1.07    | 0.82–1.39   |                 |         |
| **Cancer Diagnosis** |               |                 |         |             |                 |         |
| Colorectal           | 1.00          | 1.00            |         | 1.00        | 1.00            |         |
| Hematological        | 0.26          | 0.15–0.46       | <0.001* | 0.28        | 0.16–0.48       | <0.001* |
| Breast               | 1.00          | 0.58–1.72       | 0.98    | 0.48–1.50   | 0.577           |         |
| Lung                 | 1.01          | 0.58–1.74       | 0.985   | 0.64–1.98   | 0.682           |         |
| Liver                | 0.48          | 0.27–0.88       | 0.018*  | 0.53        | 0.29–0.96       | 0.036*  |
| Stomach              | 0.90          | 0.46–1.77       | 0.760   | 0.98        | 0.50–1.94       | 0.960   |
| Pancreas             | 1.63          | 0.78–3.41       | 0.191   | 1.73        | 0.83–3.63       | 0.147   |
| Other                | 0.80          | 0.50–1.30       | 0.372   | 0.84        | 0.52–1.36       | 0.475   |
| **Year**             |               |                 |         |             |                 |         |
| <2009                | 1.00          | 1.00            |         | 1.00        | 1.00            |         |
| ≥2009                | 0.98          | 0.76–1.27       | 0.94    | 0.72–1.23   | 0.662           |         |

*p* < 0.05.
physicians and patients regarding palliative care services in general. The percentage of home deaths remained very low and did not change throughout the study period.

A systematic review of 58 studies involving 1.5 million people from 13 countries revealed the association of 17 factors with the place of death. Six factors were found to be strongly associated with home deaths across 15 studies with high strength evidence, including patients’ low functional status (OR range 2.29–11.1), patient preferences (2.19–8.38), use of home care (1.37–5.1) and its intensity/frequency (1.06–8.65), living with relatives (1.78–7.85), and extended family support (2.28–5.47). The authors further organized these factors into groups and listed the different variables in each group (reference); they found that environmental factors had the most influence on the place of death [50].

Perhaps the strongest factor influencing the remarkably low rate of home deaths in Qatar is the lack of alternative palliative care models, such as specialized home care and hospice services. The only palliative care service available to terminal cancer patients is the acute palliative care unit. As a result, patients have no choice other than the hospital setting to meet their end-of-life palliative care needs. Not surprisingly, the lack of alternative palliative care models has affected the dynamics of our APCU. A study conducted in 2012 found that the mean length of stay for patients admitted to the APCU was the highest reported in the world [46].

### Table 4. Adjusted odds ratios and 95% CIs of variables associated with the place of death (APCU/hematology-oncology versus general medicine ward/ICU) in Qatar, 2006–2012, stratified by nationality.

|                | Qatari |               |               |               | Non Qatari |               |               |
|----------------|--------|---------------|---------------|---------------|-----------|---------------|---------------|
|                | Adjusted OR | 95% CI | p-value | Adjusted OR | 95% CI | p-value |
| Age            |         |               |               |               |           |               |
| <65 years      | 1.00   |               |               |               | 1.00      |               |
| ≥65 years      | 0.64   | 0.43–0.97     | 1.21          | 0.82–1.77     |
| Sex            |         | 0.441         |               | <0.001*      |
| Male           | 1.00   |               |               | 1.00         |
| Female         | 0.84   | 0.54–1.31     | 2.05          | 1.39–3.04    |
| Cancer Diagnosis |       |               |               |               |
| Colorectal     | 1.00   |               |               | 1.00         |
| Hematological  | 0.18   | 0.07–0.47     | <0.001*       | 0.41        | 0.20–0.83   | 0.013*        |
| Breast         | 0.60   | 0.25–1.43     | 0.250         | 1.03        | 0.48–2.20   | 0.937         |
| Lung           | 0.71   | 0.28–1.76     | 0.457         | 1.64        | 0.78–3.41   | 0.191         |
| Liver          | 0.23   | 0.08–0.57     | 0.002*        | 1.09        | 0.49–2.46   | 0.831         |
| Stomach        | 0.65   | 0.22–1.88     | 0.422         | 1.40        | 0.57–3.46   | 0.463         |
| Pancreas       | 0.86   | 0.26–2.77     | 0.794         | 3.12        | 1.17–8.31   | 0.023*        |
| Other          | 0.49   | 0.24–1.03     | 0.060         | 1.28        | 0.66–2.47   | 0.469         |
| Year           |         | 0.344         |               | 0.516       |
| <2009          | 1.00   |               |               | 1.00        |
| ≥2009          | 0.82   | 0.54–1.24     | 1.12          | 0.79–1.60    |

*p*<0.05.

doi:10.1371/journal.pone.0109615.t004

PLOS ONE | DOI:10.1371/journal.pone.0109615.t004
This issue makes the service provided in the APCU less than optimal because the actual resources available for acute cases are limited. However, the authors argued that our unit has more in common with chronic units than with an acute unit.

Several studies have documented the increased rate in home deaths (mirrored by a decreased rate of hospital deaths) in countries with established home care and hospice systems. In Edmonton, Canada, the establishment of alternative palliative care models decreased the percentage of cancer deaths in acute care hospitals from 63% to 32% \((P < .001)\) and significantly decreased the average length of stay in both acute care facilities and the cancer center. The additional new services provided that were responsible for the observed shift in the PoD included the following: establishment of hospice and home care services; palliative care teams, consisting of a consultant palliative care physician and nurse, who visit patients at home, hospice, community hospitals and continuing care facilities; increased
funding for the delivery of 24-hour palliative care at home; and increased involvement of family physicians in delivering palliative care for patients at home and in hospice care. In a prospective, non-randomized study from Sweden, terminal cancer patients who received hospital-based advanced home care were significantly less likely to die in the hospital than those who received conventional hospital care (22% vs 63%, respectively; \( p < 0.001 \)) \[52\]. This report was further supported by a systematic review by Higgins et al. where two of the six strongest factors associated with home death were use and intensity (the frequency of visits) of home care \[50\].

Given the lack of alternative palliative care modules for providing patients with the required palliative care, families tend to believe that the hospital setting, where trained physicians can provide adequate and specialized care, is the ideal place for their relatives in the end-of-life period. However, most patients would choose to have home care if they had sufficient resources at home for their palliative care needs. A public survey revealed that 47% of people wanted to spend their final days at home; 39% wanted access to a combination of home, hospital and home-like palliative care facilities; and only 3% wanted to spend their last days in a hospital ward (Fig. 3).

Our study revealed that older age (\( \geq 65 \) years) and hematologic and liver malignancies were associated with deaths in the ICU and general medicine ward in Qatari patients. In contrast, female sex and pancreatic cancers were associated with deaths in the APCU and hematology/oncology wards, whereas hematologic malignancy was associated with deaths in the ICU and general medicine wards.

There are two potential explanations for the increased risk of death in the general medicine ward and ICU in Qatari patients: one is cultural, and the other is associated with the location where patients receive their care. In Qatari culture, when the elderly become sick, they give permission for their immediate family members, such as the eldest sons, to perform the decision-making related to their care. As a result, the family’s preference plays an important role in influencing the parents’ place of death. The byproduct of this cultural practice is that the family often demands that everything be done for the parents. This becomes especially important when discussing DNR orders, which most Qatari families refuse. Consequently, elderly cancer patients are more aggressively managed until they suffer a major event, such as cardiac arrest, after which they are transferred to the ICU, where they subsequently die. A second potentially contributing factor is that elderly patients have multiple associated comorbidities, which are managed at Hamad General Hospital, where their condition may eventually deteriorate, leading to death. Furthermore, such elderly patients have a lower tolerance for cancer-related management, which puts them at an increased risk of complications in addition to their associated comorbidities.

Regarding the association between Qatari patients and liver cancer, it may be an interplay of factors related to the illness and the location where the patients receive care. Patients with liver cancer tend to have frequent exacerbations and admissions to the general medicine ward for medical and/or surgical management, such as relief of biliary obstruction, peritoneal tapping, and treatment for
peritonitis. Eventually, while they are being managed, they tend to decompensate and pass away at that location. Another possible reason may be the availability of chemoembolization, which is performed by the interventional radiologists who are situated at Hamad General Hospital. Some patients may develop complications from the procedure, especially those who have poor performance status, and then rapidly decompensate and pass away. Finally, another possible reason is that many patients present very late in the course of the disease; they are admitted to the general medicine ward and may deteriorate rapidly and pass away during the investigation of their presenting illness. Nevertheless, further research is required to elucidate whether other factors are involved.

The association between non-Qatari patients and pancreatic cancer may be related to the poor prognosis associated with the disease. Most patients have either locally advanced or metastatic cancer at initial diagnosis, and the prognosis is poor, even in those with potentially resectable disease. Despite the use of potentially curative resection, the five-year survival following surgery is only approximately 20 percent [54–57]. As a result, oncologists at our center tend to discuss the end of life with patients early, resulting in more referrals to our APCU.

Our study also found that hematologic malignancy was associated with deaths at the ICU and general medicine wards among both Qatari and non-Qatari patients. The reasons for the high hospital death rate of patients with hematologic malignancies are complex and still under investigation, but may be related to the multiple treatment options available, even at advanced stages, to patients with hematologic malignancies. As a result, the referral/transition to palliative care is
often not so apparent [58]. A recent study found that the time from diagnosis to death was a major factor influencing the place of death, with patients who died within three months of diagnosis dying in the hospital [59]. This pattern was associated with the disease sub-type, with more aggressive malignancies associated with earlier deaths, likely as a result of rapid progression without sufficient time to transition the patient to palliative care or as a result of complications of treatment [59]. A systematic review of factors influencing death at home among cancer patients also found that hematologic malignancies were associated with a lower risk of dying at home (OR 0.34–0.61) [50].

Strengths and Limitations
The strengths of this study lie in its population-based design. The data collected are inclusive of all individuals who died from cancer as the underlying cause of death during the study period. Therefore, the findings can be directly applied to inform national policies and allocate additional resources to end-of-life care.

There are several limitations to our study. First, our odds ratio analysis groups were not ideal; most place of death studies evaluate associated factors between home/hospice and hospital deaths. Second, we did not have data on individual patients’ preferences for the place of death or a clinical indication of the most appropriate place of death. Nevertheless, at the population level, the hospital is consistently considered the least preferred place of death, independent of many factors such as diagnosis, country, and setting [33]. Finally, we were not able to provide a potential explanation for the association between female non-Qataris and death at NCCCR or why liver and pancreatic malignancies were associated with nationality. Further research is needed to illuminate these findings.

Conclusion
In conclusion, a high percentage of cancer deaths in Qatar occur in the hospital. Because home is the preferred place of death for most people, effective home care and hospice programs are required to enable patients to remain at home in accordance with their preference. Furthermore, caring for such patients in the hospital will become unsustainable in terms of the capacity, cost, and patient/caregiver satisfaction/quality of life.

Acknowledgments
Dr. Reyad H. Mohsen, Dr. Laith J. Abu Raddad, Dr. Mouyyad Zaza, and Dr. Naveed Anwar for their invaluable support, encouragement, and clinical acumen. Additional support was provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at the Weill Cornell Medical College in Qatar. The statements made herein are solely the responsibility of the authors.
Author Contributions
Conceived and designed the experiments: HM PH AA AH. Performed the experiments: HM AA AH. Analyzed the data: HM PH. Contributed reagents/materials/analysis tools: HM PH. Wrote the paper: HM PH AA AH.

References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available: http://globocan.iarc.fr. Accessed 12 December 2013.
2. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, et al. (2008) Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44: 1345–1389.
3. American Cancer Society (2014) Cancer Facts & Figures. Cancer Facts Figure. Available: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed 12 December 2013.
4. Mathers CD, Loncar D (2006) Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med 3(11): e442. doi:10.1371/journal.pmed.0030442
5. Gomes B, Higginson IJ (2008) Where people die (1974—2030): past trends, future projections and implications for care. Palliat Med 22: 33–41. doi:10.1177/0269216307084606.
6. World Health Organization (2004) The solid facts: palliative care. Geneva World Heal Organ: 28. Available: http://www.euro.who.int/__data/assets/pdf_file/0003/98418/E82931.pdf. Accessed 12 December 2013.
7. World Health Organization (2004) Better Palliative Care for Older People. Available: http://www.euro.who.int/__data/assets/pdf_file/0009/98235/E82933.pdf. Accessed 12 December 2013.
8. O’Brien M, Jack B (2010) Barriers to dying at home: the impact of poor co-ordination of community service provision for patients with cancer. Health Soc Care Community 18: 337–345.
9. Gomes B, Higginson IJ, Calanzani N, Cohen J, Deliens L, et al. (2012) Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. Ann Oncol 23: 2006–2015.
10. Richards M, Department of Health (2008) End of Life Care Strategy. Available: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/136431/End_of_life_strategy.pdf. Accessed 17 December 2013.
11. Gruneir A, Mor V, Weitzen S, Truchil R, Teno J, et al. (2007) Where people die: a multilevel approach to understanding influences on site of death in America. Med Care Res Rev 64: 351–378.
12. Tang ST (2003) When death is imminent: where terminally ill patients with cancer prefer to die and why. Cancer Nurs 26: 245–251.
13. Gott M, Seymour J, Bellamy G, Clark D, Ahmedzai S (2004) Older people’s views about home as a place of care at the end of life. Palliat Med 18: 460–467.
14. Murray MA, O’Connor AM, Fiset V, Viola R (2003) Women’s decision-making needs regarding place of care at end of life. J Palliat Care 19: 176–184.
15. MacAdam M (2004) Examining Home Care in Other Countries: The Policy Issues. Home Health Care Manag Pract 16: 393–404.
16. Cohen J, Houttekier D, Onwuteaka-Philipsen B, Miccinesi G, Addington-Hall J, et al. (2010) Which patients with cancer die at home? A study of six European countries using death certificate data. J Clin Oncol 28: 2267–2273.
17. Gao W, Ho YK, Verne J, Glickman M, Higginson IJ (2013) Changing Patterns in Place of Cancer Death in England: A Population-Based Study. PLoS Med 10: e1001410.
18. Centers for Disease Control and Prevention National Center for Health Statistics (CDC NCHS) (2012) Underlying Cause of Death 1999–2010. CDC WONDER Online Database, released 2012. Available: http://wonder.cdc.gov/ucd-icd10.html. Accessed 17 December 2013.

19. World Health Organization (2004) The solid facts: palliative care. Geneva World Heal Organ: 28. Available: http://www.euro.who.int/__data/assets/pdf_file/0003/98418/E82931.pdf. Accessed 17 December 2013.

20. Escobar Pinzón LC, Weber M, Claus M, Fischbeck S, Unrath M, et al. (2011) Factors influencing place of death in Germany. J Pain Symptom Manage 41: 893–903.

21. Lin HC, Lin CC (2007) A population-based study on the specific locations of cancer deaths in Taiwan, 1997–2003. Support Care Cancer 15: 1333–1339.

22. Foreman LM, Hunt RW, Luke CG, Roder DM (2006) Factors predictive of preferred place of death in the general population of South Australia. Palliat Med 20: 447–453.

23. Menec V, Lix L, Steinback C, Ekuma O, Sirski M, et al. (2004) Patterns of Health Care Use and Costs at the End of Life. Available: http://mchp-appserv.cpe.umanitoba.ca/reference/end_of_life.pdf. Accessed 17 December 2013.

24. Riley GF, Lubitz JD (2010) Long-term trends in Medicare payments in the last year of life. Health Serv Res 45: 565–576.

25. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 103: 117–128.

26. Gomes B, Higginson IJ (2008) Where people die (1974—2030): past trends, future projections and implications for care. Palliat Med 22: 33–41.

27. Marie Curie Cancer Care (2012) Understanding the cost of end of life care in different settings. 8p., London: Marie Curie Cancer Care.

28. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, et al. (2003) The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med 138: 273–287.

29. Fisher ES, Wennberg JE (2003) Health care quality, geographic variations, and the challenge of supply-sensitive care. Perspect Biol Med 46: 69–79.

30. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ (2004) Variations in the longitudinal efficiency of academic medical centers. Health Aff (Millwood) Suppl Vari: VAR19–32. doi:10.1377/hlthaff.var.19.

31. Barnato AE, Herndon MB, Anthony DL, Gallagher PM, Skinner JS, et al. (2007) Are regional variations in end-of-life care intensity explained by patient preferences? A Study of the US Medicare Population. Med Care 45: 386–393.

32. Barnato AE, Chang C-CH, Farrell MH, Lave JR, Roberts MS, et al. (2010) Is survival better at hospitals with higher “end-of-life” treatment intensity? Med Care 48: 125–132.

33. Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, et al. (2010) Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers’ mental health. J Clin Oncol 28: 4457–4464.

34. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, et al. (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12: 160–174.

35. Lindqvist O, Tishelman C, Hagelin CL, Clark JB, Daud ML, et al. (2012) Complexity in non-pharmacological caregiving activities at the end of life: an international qualitative study. PLoS Med 9: e1001173.

36. National Center for Health Statistics (2011). Health, United States, 2010: With Special Feature on Death and Dying. Available: http://www.ncbi.nlm.nih.gov/pubmed/21634072. Accessed December 17, 2013.

37. Richards M, Department of Health (2008) End of life care strategy: promoting high quality care for all adults at the end of life. Available: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_086345.pdf. Accessed 22 December 2013.
38. European Association for Palliative Care (2010) EAPC task force on the development of palliative care in Europe. Available: http://www.eapcnet.eu/Themes/Organisation/DevelopmentinEurope.aspx. Accessed 18 December 2013.

39. Hunt RW, Bond MJ, Groth RK, King PM (1991) Place of death in South Australia. Patterns from 1910 to 1987. Med J Aust 155: 549–553.

40. Castillo-Guzmán S, Palacios-Ríos D, Nava-Obregón TA, Torres-Pérez JF, González-Santiago O (2013) Home versus hospital mortality from cancer in Mexico (1999-2009). Am J Hosp Palliat Care 30: 249–252.

41. Warren JL, Barbera L, Brenner KE, Yabroff KR, Hoch JS, et al. (2011) End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst 103: 853–862.

42. IMF (2013) World Economic Outlook Database. Available: http://www.imf.org/external/pubs/ft/weo/2013/01/weodata/index.aspx. Accessed 9 October 2013.

43. Qatar Statistics Authority (2013). Population Structure. Available: http://www.qsa.gov.qa/eng/PopulationStructure.htm. Accessed 31 December 2013.

44. World Health Organization (2012). Global Health Observatory-Qatar. Available: http://www.who.int/nmh/countries/qat_en.pdf?ua=1. Accessed 31 December 2013.

45. United Nations Department of Economic and Social Affairs (2013) World Population Prospects: The 2012 Revision. Available: http://esa.un.org/wpp/. Accessed 25 December 2013.

46. Al-Kindi SG, Zeinah GFA, Hassan AA (2013) Pattern of hospitalization of patients with cancer in an acute palliative care setting: Qatar’s experience. Am J Hosp Palliat Care 30: 25–28.

47. Beccaro M, Costantini M, Giorgi Rossi P, Miccinesi G, Grimaldi M, et al. (2006) Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC). J Epidemiol Community Health 60: 412–416.

48. Wilson DM, Truman CD, Thomas R, Fainsinger R, Kovacs-Burns K, et al. (2009) The rapidly changing location of death in Canada, 1994-2004. Soc Sci Med 68: 1752–1758.

49. Mystakidou K, Parpa E, Tsilika E, Galanos A, Patiraki E, et al. (2009) Where do cancer patients die in Greece? A population-based study on the place of death in 1993 and 2003. J Pain Symptom Manage 38: 309–314.

50. Gomes B, Higginson UJ (2006) Factors influencing death at home in terminally ill patients with cancer: systematic review. BMJ 332: 515–521.

51. Bruera E, Neumann CM, Gagnon B, Brenneis C, Kneisler P, et al. (1999) Edmonton Regional Palliative Care Program: impact on patterns of terminal cancer care. CMAJ 161: 290–293.

52. Ahlner-Elmqvist M, Jordhøy M, Jannert M, Fayers P, Kaasa S (2004) Place of death: hospital-based advanced home care versus conventional care - A prospective study in palliative cancer care. Palliat Med 18: 585–593.

53. National Health Strategy (2011). Qatar National Cancer Strategy. Available: http://www.nhsq.info/app/media/88. Accessed 17 December 2013.

54. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, et al. (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 10: 1199–210; discussion 1210–1.

55. Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223: 273–279.

56. Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, et al. (2004) Pancreatectoduodenectomy: a 20-year experience in 516 patients. Arch Surg 139: 718–25; discussion 725–7.

57. Cress RD, Yin D, Clarke L, Bold R, Holly EA (2006) Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 17: 403–409.

58. Hunt R, McCaul K (1996) A population-based study of the coverage of cancer patients by hospice services. Palliat Med 10: 5–12.
59. Howell DA, Wang H-I, Smith AG, Howard MR, Patmore RD, et al. (2013) Place of death in haematological malignancy: variations by disease sub-type and time from diagnosis to death. BMC Palliat Care 12: 42.